A B-type natriuretic peptide (BNP)-guided strategy is being widely used as a superior management technique for heart failure (HF). However, the optimal target level of BNP to improve the prognosis of HF in clinical practice remains unclear. Several studies have recently demonstrated that the existence of atrial fibrillation (AF) affects plasma BNP levels. We evaluated the prognostic value of BNP assay for HF management and found the optimal target level under the BNP-guided HF management according to the basal cardiac rhythms: AF or sinus rhythm (SR).
talization for decompensated HF brings a poor vital prognosis with frequent subsequent re-admissions, 1, 2) intervention to prevent hospitalization should help improve the prognosis in HF management. Although there are no simple clinical parameters with which to predict the early outcome, including rehospitalization, of HF patients, B-type natriuretic peptide measurements have been in the forefront of validating HF severity 3) and prognosis 4) when applying adequate HF management, 5) even for the use of general practitioners. There have been two reports demonstrating that in-hospital BNP-guided pharmacological intensification until discharge reduced the rate of re-admission. 6, 7) Atrial fibrillation is the most common sustained arrhythmia and is markedly more prevalent among HF patients than in the general population. 8) Since some clinical studies have not necessarily supported the hypothesis that the presence or development of AF in patients suffering from CHF or left ventricular dysfunction is associated with a higher mortality, 9, 10) the strategy for treatment of AF in HF patients is still controversial. 11, 12) Although some studies have recently demonstrated that the existence of AF affects plasma BNP levels in patients without HF, [13] [14] [15] [16] [17] [18] [19] there have been no reports of optimizing plasma BNP levels targeted for adequate HF management based on the basic cardiac rhythms: AF or sinus rhythm (SR).
The aims of this study, therefore, were to determine the prognostic value of BNP assay for HF management irrespective of basic cardiac rhythms and to find the practically available BNP levels to be targeted under BNP-guided management in HF patients with AF or SR, separately.
METHODS

Patients:
The study population consisted of a consecutive series of patients admitted to Kitasato University Hospital for HF exacerbation diagnosed by generally accepted Framingham criteria from January 1996 to September 2002. Patients with acute myocardial infarction, renal dysfunction with serum creatinine levels > 1.5 mg/dL, unachieved predischarge BNP measurements, and without follow-up outpatient management in this hospital were excluded. The 240 remaining patients were stratified into 2 groups according to their basic cardiac rhythms during hospitalization, 111 with AF and 129 with SR. To compare the influence of persistent cardiac rhythms on plasma BNP levels, patients with intermittent AF, including 41 with successful defibrillation and 12 with spontaneous paroxysmal AF, were not included. Therefore, in the end 129 patients with SR and 58 with chronic AF were included in the derivation study described below. Study design: A decision concerning hospital discharge during this study period was made by 2 experienced cardiologists using conventional analysis based on a physical exam, logical assays, chest X-rays, and an echocardiogram. Patients were discharged when they presented no more signs of HF decompensation under optimal drug administration including diuretics and angiotensin-converting enzyme inhibitors. The endpoints, which were cardiac events including total 3)** NYHA = New York Heart Association functional class; U = undetermined; LAD = left atrial dimension; LVDd = left ventricular end-diastolic dimension; LVEF = left ventricular ejection fraction; BNP = Btype natriuretic peptide; IHD = ischemic heart disease; DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; VHD = valvular heart disease; HHD = hypertensive heart disease; DM = diabetes mellitus; HT = hypertension; CVD = cerebrovascular disease; ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blockers. * and ** P < 0.05 and P < 0.01 versus SR group, respectively.
death and re-hospitalization for HF exacerbation, were retrospectively analyzed in every case from hospital discharge until September 2002 (follow-up period; range, 1-72 months; mean, 33.0 ± 22.0 months). The clinical relationship between these endpoints and predischarge plasma BNP levels was analyzed. Natriuretic peptide measurement: Venous blood samples for natriuretic peptides were obtained from an antecubital vein after 15 minutes of rest on admission and within 3 days before hospital discharge as 'predischarge'. Blood was immediately transferred to chilled disposable tubes containing disodium EDTA (1 mg/mL) and aprotinin (500 U/mL), and centrifuged at 4°C. Plasma ANP and BNP were determined directly by a sensitive noncompetitive immunoradiometric assay kit (Shionoria ANP ® and Shionoria BNP ® , Shionogi & Co., Ltd., Osaka, Japan). Clinical estimation of HF status: Clinical parameters on admission and discharge were analyzed as patient baseline characteristics for HF. M-mode images of echocardiography were obtained in left parasternal long-axis views using a SONOS 500 echocardiogram (Hewlett Packard, USA) to measure chamber dimensions of the left atrium and ventricle (LAD, LVDd, respectively). The left ventricular ejection fraction (LVEF) was derived from 2-dimensional apical 4-chamber views with a modified Simpson's rule algorithm. The medications prescribed on discharge for HF management are shown in the Table. Statistical analysis: Continuous data are expressed as the mean ± SD. Patient characteristics were compared using the chi-squared test and Mann-Whitney Utest. Receiver-operating characteristic (ROC) curves were calculated for prediction of cardiac events during the 36 month period after discharge using plasma BNP levels. Sensitivity, specificity, and area under ROC curve (AUC) were computed for BNP using SPSS software (11.0.1J for Windows, SPSS Inc., Chicago, USA). Kaplan-Meier survival analysis was used to estimate the event-free rates for patients among each stratified group according to plasma BNP levels, and the significance of differences was calculated using the log-rank test. Statistical significance was defined as a P value < 0.05 (one-sided) for all analyses.
RESULTS
Patient characteristics and clinical outcome in SR and CAF groups:
The patient characteristics are shown in the Table. Although the average age of the patients was significantly higher in the CAF group than that in the SR group, the difference between the 2 groups was no more than 4 years. There was no significant difference in HF severity according to New York Heart Association (NYHA) functional classes or plasma levels of natriuretic peptides between the 2 groups, although some differences were observed for LAD, LVDd, LVEF, basal heart Vol 46 No 3 diseases, and the frequency of digitalis and warfarin administration. In both groups, more than 95% of the patients were NYHA class III or IV at the time of admission, while more than two-thirds were NYHA class I or II upon discharge. Mean BNP levels were 712 ± 515 and 495 ± 415 pg/mL on admission, and 187 ± 242 and 176 ± 158 pg/mL at predischarge in the SR and CAF groups, respectively. The Kaplan-Meier survival curves demonstrated that there was no significant difference in cardiac events, including the total number of deaths and rehospitalization for HF exacerbation after discharge (Figure 1 ), between the SR and CAF groups.
Cut-off values for predischarge BNP as a predictor for subsequent HF events:
Patients who could be followed-up for more than 36 months after discharge (76 in the SR group and 27 in the CAF group), were included in the analysis to calculate cut-off values for predischarge BNP to predict HF events after discharge. The ROC curves in Figure 2 demonstrate that the predischarge BNP level was the value most strongly associated with a cardiac event (death or rehospitalization) for HF exacerbation, and to distinguish a difference between the 2 groups (AUC of 0.72 in the SR group and 0.82 in the CAF group). Applying the defined predischarge BNP cut-off level of 125 pg/mL, a cardiac event at 36 months was predicted with a sensitivity of 64% and a specificity of 65% in the SR group ( Figure  2A) . Similarly in the CAF group, the predischarge BNP cut-off level was 165 pg/ mL with a sensitivity of 71% and a specificity of 79% ( Figure 2B ). Clinical outcome stratified according to predischarge BNP: Patients in the SR group were stratified into semiquartile subgroups according to the predischarge plasma BNP of 125 pg/mL as the ROC-derived cut-off level and 200 pg/mL as the former targeted level under BNP-guided HF management in this department 7) : < 50 pg/mL (n = 33), 50-125 pg/mL (n = 41), 125-200 pg/mL (n = 19) and > 200 pg/mL (n = 36). Kaplan-Meier curves demonstrated that the risk of a cardiac event increased in stepwise fashion across an increasing predischarge BNP range. The clinical outcome concerning cardiac events in the subgroup with a predischarge BNP > 200 pg/mL was statistically compared with those of the other 3 subgroups of < 200 pg/mL ( Figure 3A ). There was no significant difference in the rate of cardiac events between the > 200 pg/mL and 125-200 pg/mL subgroups. The rate of cardiac events in the 2 subgroups < 125 pg/mL (< 50 pg/ mL and 50-125 pg/mL), however, was significantly decreased compared with that in the > 200 pg/mL subgroup, while there was no significant difference in the morbidity between the two < 125 pg/mL subgroups (< 50 pg/mL and 50-125 pg/ mL).
The CAF group patients were also stratified into semiquartile subgroups according to a predischarge plasma BNP level of 165 pg/mL as the ROC-derived cut-off level and 200 pg/mL as the former targeted level for BNP-guided strategy: Figure 2 . Receiver-operating characteristic (ROC) curve values for BNP at predischarge in predicting cardiac events during 36 month period after discharge in the CAF and SR groups. The BNP cut-off level was 125 pg/mL (sensitivity; 64%, specificity; 65%, and AUC; 0.72) in the SR group and 165 pg/mL (sensitivity; 71%, specificity; 79%, and AUC; 0.82) in the CAF group. The cut-off level was higher in the CAF group than in the SR group.
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< 100 pg/mL (n = 24), 100-165 pg/mL (n = 11), 165-200 pg/mL (n = 6) and > 200 pg/mL (n = 17). The clinical outcome concerning cardiac events in the predischarge BNP > 200 pg/mL subgroup was statistically compared with those in the three < 200 pg/mL subgroups ( Figure 3B ). There was no significant difference in A B Figure 3 . A: Kaplan-Meier estimates of cardiac event-free survival among subgroups according to BNP level at predischarge in the SR group. Compared with the > 200 pg/mL subgroup, there was no significant difference in the prognosis of patients in the 125-200 pg/mL subgroup, but the prognosis was better in the < 50 pg/mL and 50-125 pg/mL subgroups. Moreover, among the two < 200 pg/mL subgroups, there was no significant difference in prognosis. B: Kaplan-Meier estimates of cardiac event-free survival among subgroups according to BNP level at predischarge in the CAF group. Compared with the >200 pg/mL subgroup, there was no significant difference in the prognosis of patients in the 165-200 pg/mL subgroup, but the prognosis was better in the < 100 pg/mL and 100-165 pg/mL subgroups. Moreover, among the two < 165 pg/mL subgroups, there was no significant difference in prognosis. * P < 0.05 morbidity between the > 200 pg/mL and 165-200 pg/mL subgroups. The incidence of cardiac events in the two < 165 pg/mL subgroups (< 100 pg/mL and 100-165 pg/mL), however, was significantly decreased compared with that in the > 200 pg/mL subgroup, while there was no significant difference in morbidity between the two < 165 pg/mL subgroups (< 100 pg/mL and 100-165 pg/mL).
DISCUSSION
Optimization of plasma BNP for practical HF management: It is difficult to estimate disease severity for HF and the adequacy of a management strategy, especially for general practitioners because there are no simple criteria or scores with which to predict a prognosis using conventional examinations. Plasma BNP measurement may be a good candidate for this purpose because of its convenient, accurate, uniform, and reproducible characteristics. A BNP-guided strategy has been widely used and its use is increasing because of its superiority with respect to HF management with empirical trial-based therapy. Since the mean value of plasma BNP at predischarge in HF patients who did not require readmission for HF exacerbation was 160 pg/mL, 20) we assumed that BNP-guided management, in which drug medication was attempted and intensified until the plasma concentration of BNP decreased below 200 pg/mL during admission even if the clinical target had been achieved, could improve the cardiovascular event-free survival of HF. During the follow-up period after discharge, there were significantly fewer total cardiovascular events after the introduction of a BNP-management strategy than before. 7) However, there have been no reports concerning the optimization of targeted BNP levels. What is the optimal target of plasma BNP for HF management practically? The stepwise increase in the risk of a cardiac event across an increasing predischarge BNP range observed in the Kaplan-Meier curves implied that the greater the degree of decrease in the plasma BNP at predischarge was, the more improved was the prognosis.
However, the less an increased risk of a cardiac event is observed under a certain decreased BNP range, the less the gain in therapeutic benefit, even if the HF management regime is further intensified. This concept must lead to the establishment of an 'optimal plasma BNP level' to be targeted in clinical practice. In the present study, stratified subgroup analysis using the Kaplan-Meier method demonstrated that the risk of a cardiac event was decreased in a stepwise manner across a decreasing predischarge BNP range above 125 pg/mL as the ROCderived cut-off level, while a less decreased risk for a cardiac event was observed for a decreased BNP range below 125 pg/mL in the SR group. A similar pattern was observed around the distinguishable BNP level of 165 pg/mL in the CAF group. It can be surmised, therefore, that the practically optimal target levels of Vol 46 No 3 plasma BNP at predischarge to improve prognosis should be different and distinguishable between the SR and CAF groups: 125 pg/mL and 165 pg/mL, respectively. Adequacy of HF management in SR and CAF: In the process of investigating the difference in optimal target levels for plasma BNP between the SR and CAF groups, it should be confirmed if there is any difference in the adequacy and intensity of HF management between the groups. Although it is difficult to prove a similar degree of adequacy for HF management, there was no significant difference in predischarge HF severity according to NYHA functional classes and plasma levels of BNP between the groups. Furthermore, the survival curves demonstrated that there was no significant difference in the prognosis between the 2 groups ( Figure 1 ). Although the prognostic significance of AF in HF remains poorly understood, the vast majority of clinical studies have supported the hypothesis that the presence or development of AF in patients suffering from HF is associated with a deteriorated 21) or neutral 9) impact on the prognosis of HF. It can therefore be presumed that there was no noteworthy disparity in the adequacy and intensity of HF management between the SR and CAF groups. Impact of AF on plasma BNP in HF patients: A derivation and validation study demonstrated here that there was a difference in the supposed optimal target of plasma BNP at predischarge for HF management of 40 pg/mL between the SR and CAF groups. Several studies have reported on the modification of plasma BNP levels in existing AF. Other than the report by Rossi, et al 22) most of the studies demonstrated that plasma BNP levels increased significantly (about 30-100 pg/mL) in conjunction with the occurrence or coexistence of AF. [13] [14] [15] [16] [17] [18] The mechanisms by which the BNP level increases in patients with AF are not well known. 23) Explanations involving two pathomechanisms have been proposed: derivative BNP production primarily by AF and cardiac loading secondarily by AF. Irregular ventricular rhythm during AF can contribute to impairment of cardiac function, 24) leading to increased wall stress in the ventricles. It has been suggested, on the other hand, that BNP may be excreted from not only ventricles but also atria and that AF induces increased atrial excretion of BNP, 14, [25] [26] [27] partly through elevated atrial pressure or atrial dilatation. 25) However, AF is not always coincident with elevated atrial pressure. 28) LAD does not always regress together with decreased levels of plasma BNP when restoring AF to SR. 14) Pronounced BNP production, therefore, may not necessarily be induced by a reversal, transient atrial loading, or disconfiguration. Since atrial biopsy specimens from patients with lone CAF demonstrate severely-impaired myocardial hypertrophy, fibrosis, and inflammation ,29) these irreversible pathological changes may lead to an enhanced production of BNP in the atrial myocardium similar to that seen in the ventricles. 23) There have been few investigations on whether BNP values are modified by AF in patients with HF. We were able to demonstrate here a higher optimal target of plasma BNP in CAF than in SR for adequate HF management, implying that chronically complicated AF could affect increased levels of plasma BNP even in HF patients. Clinical implications: The plasma level of BNP is modulated [30] [31] [32] [33] [34] [35] [36] via a balance between the myocardial production and peripheral clearance 37) of BNP. It has been argued concerning the efficacy or practical methodology of BNP-guided HF management, irrespective of many factors affecting plasma BNP values, that it is necessary to modify optimal target levels of plasma BNP according to the patient background. Since we demonstrated from the viewpoint of basal cardiac rhythms that there is a difference in optimal target BNP levels as great as 40 pg/mL between the SR and CAF groups, how to set lower target levels for BNP in HF patients with SR than in those with CAF (125 pg/mL and 165 pg/mL, respectively) must be taken into consideration. Study limitations: The study was carried out at a single center in both a retrospective and nonrandomized fashion. The data obtained may have been biased since the clinical judgment depended on the clinical status of each patient. Furthermore, the ideal scenario is that there would be no significant difference in clinical background between SR and CAF patients. This is impossible, however, since AF itself may lead to pathological and hemodynamic changes. This is one limitation of this study that needs to be acknowledged.
Among several clinical features that are significantly different between the SR and CAF groups, it is assumed that greater age and more frequent valvular heart diseases (VHD) in the CAF group could be factors to raise plasma BNP levels based on previous reports. It has been reported that plasma BNP levels increase significantly with age, although the mechanism remains uncertain. The difference is, however, only 10-15 pg/mL per 10 years of age; 32) therefore, it is difficult to conclude this led to a difference of 40 pg/mL in the BNP level when the age difference was only less than 4 years between the 2 groups in this study. On the other hand, the most prevalent VHD (42%, 11 out of 26 VHD) in CAF was mitral regurgitation (MR). Although several studies have reported that plasma BNP levels increase with the severity of MR, 38, 39) all of these retrospective analyses were achieved irrespective of basal cardiac rhythms and some clinical parameters of HF status. At present, therefore, it is difficult to conclude that the coexistence of MR itself contributes to the elevation of plasma BNP independently from other associated factors.
Despite these limitations, our study focused for the first time on the clinical significance of basal cardiac rhythms, SR or CAF, when establishing optimal target levels for plasma BNP in HF management. Further investigations addressing 
